CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Revenues
Product sales	$ 2,186,000,000	$ 2,443,000,000	$ 6,462,000,000	$ 7,168,000,000
Other revenues	33,000,000	36,000,000	99,000,000	103,000,000
Total revenues	2,219,000,000	2,479,000,000	6,561,000,000	7,271,000,000
Expenses
Cost of goods sold (excluding amortization and impairments of intangible assets)	650,000,000	649,000,000	1,869,000,000	1,917,000,000
Cost of other revenues	9,000,000	9,000,000	32,000,000	29,000,000
Selling, general and administrative	623,000,000	661,000,000	1,943,000,000	2,145,000,000
Research and development	81,000,000	101,000,000	271,000,000	328,000,000
Amortization of intangible assets	657,000,000	664,000,000	1,915,000,000	2,015,000,000
Goodwill impairments		1,049,000,000	312,000,000	1,049,000,000
Asset impairments	406,000,000	148,000,000	629,000,000	394,000,000
Restructuring and integration costs	6,000,000	20,000,000	42,000,000	78,000,000
Acquired in-process research and development costs	0	31,000,000	5,000,000	34,000,000
Acquisition-related contingent consideration	(238,000,000)	9,000,000	(297,000,000)	18,000,000
Other (income) expense, net	(325,000,000)	1,000,000	(584,000,000)	(20,000,000)
Total expenses	2,181,000,000	3,342,000,000	6,137,000,000	7,987,000,000
Operating income (loss)	38,000,000	(863,000,000)	424,000,000	(716,000,000)
Interest income	3,000,000	3,000,000	9,000,000	6,000,000
Interest expense	(459,000,000)	(470,000,000)	(1,392,000,000)	(1,369,000,000)
Loss on extinguishment of debt	(1,000,000)	0	(65,000,000)	0
Foreign exchange and other	19,000,000	(2,000,000)	87,000,000	4,000,000
Loss before recovery of income taxes	(400,000,000)	(1,332,000,000)	(937,000,000)	(2,075,000,000)
Recovery of income taxes	(1,700,000,000)	(113,000,000)	(2,829,000,000)	(179,000,000)
Net income (loss)	1,300,000,000	(1,219,000,000)	1,892,000,000	(1,896,000,000)
Less: Net (loss) income attributable to noncontrolling interest	(1,000,000)	(1,000,000)	1,000,000	(2,000,000)
Net income (loss) attributable to Valeant Pharmaceuticals International, Inc.	$ 1,301,000,000	$ (1,218,000,000)	$ 1,891,000,000	$ (1,894,000,000)
Earnings (loss) per share attributable to Valeant Pharmaceuticals International, Inc.:
Basic (in usd per share)	$ 3.71	$ (3.49)	$ 5.40	$ (5.47)
Diluted (in usd per share)	$ 3.69	$ (3.49)	$ 5.38	$ (5.47)
Weighted-average common shares
Basic (in shares)	350.4	349.5	350.1	346.5
Diluted (in shares)	352.3	349.5	351.4	346.5